A method for supplementing dietary potassium, magnesium and citrate is disclosed that comprises orally administering an effective amount of potassium magnesium citrate in a single salt. Methods for decreasing urinary calcium and oxalate by the administration of potassium magnesium citrate in a single salt are also disclosed.
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a continuation of application Ser. No. 437,938, filed Nov. 16, 1989, now abandoned, which is a continuation-in-part of application Ser. No. 07/303,536, filed Jan. 27, 1989, now U.S. Pat. No. 4,895,980 which is a divisional of application Ser. No. 07/140,818, filed Jan. 5, 1988 now U.S. Pat. No. 4,985,593.
A specific form of a dual mineral salt having potassium, magnesium, and citrate in a stoichiometric ratio of potassium:magnesium of less than 4:1 is disclosed. Methods of making the composition and using the composition as a dietary supplement are also disclosed.
A composition useful as a dietary supplement for providing potassium, calcium, and citrate is presented, as well as processes for producing the composition, and methods for using the composition as a dietary supplement. Administration of the composition counters bone loss associated with aging or menopause by providing bioavailable calcium and, simultaneously, delivering alkali load. In addition, administration of the composition produces a substantial increase in urinary citrate, which counters kidney-stone formation.
A vitamin and mineral supplement containing ULTRADENSE.TM. calcium citrate and carbonyl iron for use in humans. Calcium in the form of citrate enhances absorption of iron, zinc, and magnesium. ULTRADENSE.TM. calcium citrate provides more bioavailable calcium than usual preparations of calcium citrate. Carbonyl iron provides iron in a form that significantly reduces the risk to children of accidental iron poisoning from formulations that provide iron in salt form. The supplement may further contain a number of vitamins and minerals in a tablet that is elegantly small, weighing about 1.5-1.6 g. The small size allows ease of swallowing and encourages patient acceptability. Methods of making such a supplement and methods of treating maladies in need of vitamin and mineral supplementation are provided.
A combination of the following active ingredients for treating osteoporosis: (a) a pharmacologically-acceptable alkalinizing potassium salt which produces hydroxyl ions and is thereby capable of reducing the acidity of tissue fluids or urine and which is selected from the group consisting of potassium bicarbonate and potassium salts of carboxylic acids which are transformed to bicarbonate and thus alkalinize in vivo; and (b) a thiazide diuretic.
A magnesium citrate oral solution comprising citric acid in an amount greater than 10% weight/volume; magnesium hydroxide in an amount ranging from about 1.5-5% weight/volume; and water. Most preferably, the citric acid is present in an amount of about 10.9% weight/volume. Another embodiment of the present invention is a method of treating constipation in a patient in need thereof. The method of this embodiment comprises administering an effective amount of an oral composition that comprises citric acid in an amount greater than 10% weight/volume. Preferably, the composition of this embodiment comprises citric acid in an amount of 10.9% weight/volume.
